Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Inhibrx Biosciences Inc
(NQ:
INBX
)
13.96
-0.23 (-1.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Inhibrx Biosciences Inc
< Previous
1
2
3
Next >
Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying
August 27, 2024
Via
Benzinga
INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024
August 22, 2024
INBX stock results show that Inhibrx beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
INBX Stock Earnings: Inhibrx Biosciences Beats EPS for Q2 2024
August 14, 2024
INBX stock results show that Inhibrx Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Top 4 Health Care Stocks That Are Preparing To Pump This Month
June 05, 2024
Via
Benzinga
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
May 09, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
JMP Securities Maintains Outperform Rating for Inhibrx: Here's What You Need To Know
August 23, 2023
Via
Benzinga
Inhibrx Resumes Patient Enrollment In INBRX-109 Studies In Cancer Patients
April 26, 2023
Via
Benzinga
Why Is Inhibrx (INBX) Stock Soaring 45% Today?
October 04, 2022
Inhibrx received a vote of confidence from the Food and Drug Administration, skyrocketing the largely speculative INBX stock.
Via
InvestorPlace
The NVDA Earnings Effect And What It Means For The Current Market Momentum
February 28, 2024
Discover the confluence zone that will make or break the S&P 500 and the preliminary supply (early distribution) you need to be aware of.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Is The Stock Market Ready To Plunge? The Warning Signs Are Here...
February 21, 2024
Find out how to spot the exhaustion of demand and the bearish analogue you could refer to to anticipate the down move.
Via
Talk Markets
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
February 10, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx
January 23, 2024
The company is buying Inhibrx, which is working on a treatment for alpha-1 antitrypsin deficiency.
Via
Investor's Business Daily
Inhibrx's Experimental Drug For Inherited Disease Capable For Accelerated FDA Approval, Shares Surge
October 04, 2022
Via
Benzinga
INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders
January 23, 2024
From
Halper Sadeh LLC
Via
Business Wire
French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B
January 23, 2024
Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected...
Via
Benzinga
Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project
January 23, 2024
Following the acquisition, New Inhibrx will continue to operate under the "Inhibrx" name, with Mark Lappe as Chairman and CEO.
Via
Benzinga
$1.5M Bet On Domo? Check Out These 3 Stocks Insiders Are Buying
August 31, 2023
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.
Via
Benzinga
Why NIO Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
August 29, 2023
Gainers Axcella Health Inc. (NASDAQ: AXLA) shares climbed 196% to $0.3335 after the company announced it was granted a patent for long COVID fatigue treatment.
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday
August 29, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating
May 03, 2023
On Wednesday, Inhibrx stock now clears that desired 80-plus Relative Strength threshold, with a jump from 80 to 86 Wednesday.
Via
Investor's Business Daily
Inhibrx Posts Updated Efficacy, Safety Data From Expansion Cohorts Of Bone Cancer Candidate
November 16, 2022
Via
Benzinga
$40 Million Bet On Inhibrx? 3 Stocks Insiders Are Buying
October 13, 2022
Although US stocks closed slightly lower on Wednesday, there were a few notable insider trades.
Via
Benzinga
Stocks Reverse Gains After ADP Report
October 05, 2022
Wall Street's rally has come to a screeching halt, as Treasury yields tick higher once again.
Via
Talk Markets
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
November 18, 2022
Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday.
Via
Benzinga
S&P 500 Rises 100 Points; Nasdaq Up 3%
October 04, 2022
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 300 points on Tuesday.
Via
Benzinga
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
October 05, 2022
Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 04, 2022
Gainers
Via
Benzinga
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session
October 04, 2022
Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday.
Via
Benzinga
Nasdaq Surges 350 Points; Crude Oil Rises Sharply
October 04, 2022
U.S. stocks traded higher midway through trading, with the Nasdaq Composite climbing more than 350 points on Tuesday.
Via
Benzinga
US Stocks Open Higher As Dow Jumps 550 Points
October 04, 2022
U.S. stocks traded higher this morning, with the Dow Jones climbing more than 550 points on Tuesday.
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.